Alzamend Neuro (ALZN) Price & Analysis

Compare

377 Followers

ALZN Stock Chart & Stats

$2.15

-$0.10(-8.06%)

At close: Jan 08 4:00 PM EST

$2.15

-$0.10(-8.06%)

Day’s Range― - ―

52-Week Range$1.88 - $12.06

Previous Close$1.15

Volume144.13K

Average Volume (3M)146.22K

Market Cap

$8.17M

Enterprise ValueN/A

Total Cash (Recent Filing)$4.45M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.64

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.06

Shares Outstanding3,801,604

10 Day Avg. Volume147,464

30 Day Avg. Volume146,221

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.67

Price to Sales (P/S)0.00

P/FCF Ratio-0.39

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$42.00

Price Target Upside1853.49% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe company reported positive Top-line results from the Phase 2 study for AL001, which is a positive development for the stock.

Financial StabilityThe company has enough cash to sustain operations until late-2025, providing financial stability for ongoing research and development activities.

ValuationThe current valuation is considered attractive, with a maintained BUY rating, reflecting a balance between high risks and large upside opportunities.

Bears Say

Financial PositionThe company remains in a challenging financial position (including potential dilution from convertible securities) and will likely require additional capital before it can move into patients.

Alzamend Neuro News

Alzamend Neuro completes clinical portion of Phase II clinical study of AL001

Alzamend Neuro (ALZN) announced completion of the clinical portion of its first Phase II clinical study of AL001,...

30d ago

ALZN

Alzamend Neuro Mourns Loss of Director Andrew Woo

Alzamend Neuro ( ($ALZN) ) just unveiled an announcement. Alzamend Neuro, Inc. announced the passing of Andrew H....

1M ago

ALZN

Alzamend Neuro Issues New Common Stock Shares

Alzamend Neuro ( ($ALZN) ) has provided an announcement. Between October 1 and October 8, 2025, Alzamend Neuro,...

2M ago

ALZN

Alzamend Neuro Boosts Liquidity with Stock Issuance

Alzamend Neuro ( ($ALZN) ) has provided an update. Between September 17 and September 25, 2025, Alzamend Neuro,...

3M ago

ALZN

Alzamend Neuro Increases Common Stock Through Conversion

Alzamend Neuro ( ($ALZN) ) has issued an announcement. Between July 23, 2025, and July 30, 2025, Alzamend...

5M ago

ALZN

Alzamend Neuro to present at Military Health System Research Symposium

Alzamend Neuro (ALZN) will have a poster presentation at the Military Health System Research Symposium, being held from...

5M ago

ALZN

Alzamend Neuro reports FY25 net cash provided by financing activities of $10.4M

Alzamend Neuro (ALZN) reported its financial results for the year ended April 30, 2025, which were disclosed on...

5M ago

ALZN

Alzamend Neuro announces final closing of $5M private placement

Alzamend Neuro (ALZN) has completed the final closing of its $5 million private placement. As previously reported, on...

6M ago

ALZN

Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update

Alzamend Neuro stock rocketed on Thursday after the company announced an update to a Phase II clinical study of AL001. ...

7M ago

ALZN

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories

Earnings reports, trade war updates, and AI developments dominate the morning news cycle on Thursday. ...

7M ago

Alzamend Neuro doses first patient in Phase II study of AL001

Alzamend Neuro (ALZN) announced the dosing of the first patient of its first Phase II clinical study of...

7M ago

ALZN

Alzamend Neuro enrolls first patient in Phase II trial of AL001

Alzamend Neuro (ALZN) announced the enrollment of the first patient of its first Phase II clinical study of...

7M ago

ALZN

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

7M ago

INM

XLO

Alzamend Neuro initiates first Phase II trial of AL001

Alzamend Neuro (ALZN) announced the initiation of the first of five Phase II clinical studies of AL001, with...

7M ago

ALZN

ALZN FAQ

What was Alzamend Neuro’s price range in the past 12 months?

Alzamend Neuro lowest stock price was $1.88 and its highest was $12.06 in the past 12 months.

What is Alzamend Neuro’s market cap?

Alzamend Neuro’s market cap is $8.17M.

When is Alzamend Neuro’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Alzamend Neuro’s earnings last quarter?

Alzamend Neuro released its earnings results on Mar 15, 2022. The company reported -$40.5 earnings per share for the quarter, the consensus estimate of -$40.5 by $0.

Is Alzamend Neuro overvalued?

According to Wall Street analysts Alzamend Neuro’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alzamend Neuro pay dividends?

Alzamend Neuro does not currently pay dividends.

What is Alzamend Neuro’s EPS estimate?

Alzamend Neuro’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzamend Neuro have?

Alzamend Neuro has 3,801,604 shares outstanding.

What happened to Alzamend Neuro’s price movement after its last earnings report?

Alzamend Neuro reported an EPS of -$40.5 in its last earnings report, expectations of -$40.5. Following the earnings report the stock price went down -4.798%.

Which hedge fund is a major shareholder of Alzamend Neuro?

Currently, no hedge funds are holding shares in ALZN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzamend Neuro

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Alzamend Neuro (ALZN) Earnings & Revenues

Historic Earnings Reports

ALZN Stock 12 Month Forecast

Average Price Target

$42.00

▲(1853.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","804":"$804","1607":"$1,607","402.5":"$402.5","1205.5":"$1,205.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,402.5,804,1205.5,1607],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Aug<br/>2023","9":"Feb<br/>2024","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,5.464615384615384,8.509230769230768,11.553846153846154,14.598461538461537,17.64307692307692,20.68769230769231,23.732307692307693,26.776923076923076,29.82153846153846,32.86615384615384,35.910769230769226,38.95538461538462,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,5.464615384615384,8.509230769230768,11.553846153846154,14.598461538461537,17.64307692307692,20.68769230769231,23.732307692307693,26.776923076923076,29.82153846153846,32.86615384615384,35.910769230769226,38.95538461538462,{"y":42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,5.464615384615384,8.509230769230768,11.553846153846154,14.598461538461537,17.64307692307692,20.68769230769231,23.732307692307693,26.776923076923076,29.82153846153846,32.86615384615384,35.910769230769226,38.95538461538462,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1212.03,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1263.6,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1606.5,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1566,"date":1669852800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":573.75,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1043.55,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":633.15,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.92,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.82,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.41,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >